Welcome to our dedicated page for Genenta Science S.p.A. American Depositary Shares news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science S.p.A. American Depositary Shares stock.
Genenta Science S.p.A. (symbol: GNTA) is a cutting-edge biotechnology company specializing in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and various types of cancer. The company leverages an innovative gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression specifically to tumor-infiltrating monocytes/macrophages. Utilizing a genetically modified, HIV-derived lentiviral vector, Genenta delivers the therapeutic gene into HSPCs, enabling these cells to selectively express interferon within the tumor microenvironment, thereby minimizing systemic toxicity.
One of Genenta's flagship products, Temferon, is designed to treat glioblastoma multiforme, a highly aggressive brain tumor. Another key product focuses on TIE2-expressing monocytes (TEMs), which are engineered to attack solid tumors using an innovative combination of transcriptional and microRNA-mediated control mechanisms.
In recent developments, Genenta Science has expanded its research to include refractory advanced genitourinary malignancies, such as renal cell cancer, as a second indication. The company's latest news highlights preliminary data from its ongoing Phase 1/2 clinical trials, demonstrating promising results in the dose-ranging stage.
With its headquarters in Milan, Italy, and extensive clinical operations in New York, Genenta Science is at the forefront of immuno-oncology, aiming to harness the body's own immune system to combat cancer effectively and safely. The company remains committed to advancing its pipeline and achieving breakthroughs in cancer treatment.
- Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication.
- Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial.
Genenta Science (NASDAQ: GNTA) announced that the FDA has granted Orphan Drug Designation to Temferon™ for glioblastoma multiforme (GBM) treatment. The designation aims to promote the development of Temferon™, a cell therapy targeting tumor microenvironments with immunomodulatory molecules. This decision is expected to enhance Genenta's clinical program addressing the significant unmet medical need in GBM, where about 60% have unmethylated MGMT promoter status. The ODD provides benefits such as federal grants, tax credits for trials, and a seven-year marketing exclusivity post-approval.
Genenta Science (NASDAQ: GNTA) has announced a development and manufacturing service agreement with AGC Biologics S.p.A. to produce cell therapy lentivirus-based products for its clinical programs. This partnership aims to enhance Genenta's ongoing Phase 1/2 clinical trial, particularly for its treatment targeting glioblastoma multiforme. Following the acquisition of Molecular Medicine's facility by AGC Biologics, the collaboration indicates a strategic expansion, emphasizing the importance of the manufacturing process in clinical progression. CEO Pierluigi Paracchi highlighted expectations for their treatment to significantly impact solid tumors.
Genenta Science (Nasdaq: GNTA) will present data at the Society for Immunotherapy of Cancer's annual meeting, indicating that its product candidate, Temferon, has induced a pro-inflammatory state in glioblastoma patients, potentially inhibiting tumor growth. Preclinical studies suggest that Temferon activates immune responses linked to tumor responses and eradication in certain cases. The CEO highlighted the unmet need in glioblastoma treatment, suggesting Temferon's potential as a disease-modifying intervention. The findings will be presented in Boston from November 8-12, 2022.
Genenta Science (Nasdaq: GNTA) released its financial results for the six months ended June 30, 2022, reporting a net loss of €2.1 million, a reduction from a €4.0 million loss in the same period last year. The company has no revenues but holds €34.7 million in cash, sufficient to fund operations through 2024. Significant progress was made in the Phase 1/2a trial of Temferon for glioblastoma, with a median overall survival of 17 months reported. The trial has escalated to a higher dosing cohort and aims to assess new conditioning regimens for enhanced efficacy.
Genenta Science (NASDAQ: GNTA), a clinical-stage immune-oncology company, is set to showcase its innovative therapies at upcoming scientific and investor conferences. Key events include the Roth Inaugural Healthcare Opportunities on October 6 in New York and the European Society of Gene & Cell Therapy Congress from October 11-14 in Edinburgh, UK. The Society for Immunotherapy of Cancer’s Annual Meeting will follow from November 8-12 in Boston, MA. These presentations will feature groundbreaking research on genetically-modified hematopoietic stem cells and autologous macrophage-based immunotherapy targeting solid tumors.
Genenta Science (NASDAQ: GNTA) will present at several major investor conferences in September and October 2022. CEO Pierluigi Paracchi and CMO Carlo Russo will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13. They will also participate in a panel at the Cantor Fitzgerald’s Cell and Genetic Medicines Conference on September 15, focusing on manufacturing essentials. Lastly, they will present at Chardan’s 6th Annual Genetic Medicines Conference on October 3. More details and the investor presentation can be found on their investor relations page.
Bowling Green Bull (BGB) is a new initiative launched to connect Italian companies and entrepreneurs seeking growth in the U.S. financial markets. Supported by the American Chamber of Commerce in Italy and Genenta Science (Nasdaq: GNTA), BGB aims to facilitate interactions between listed and aspiring listed companies, banks, and advisors. The inaugural event is scheduled for autumn 2022, focusing on providing insights and guidelines for Italian firms navigating U.S. market entry.
Genenta Science (NASDAQ: GNTA) announced its participation in several scientific congresses in May and June 2022, showcasing advancements in immuno-gene therapy for cancer. Presentations include:
- ASGCT Annual Meeting: May 19 - TEM-GBM study findings.
- Brain Tumor Meeting: May 19-20 - Patient case using Temferon™.
- ASCO Annual Meeting: June 5 - Tumor immune microenvironment research.
- EHA Virtual Congress: June 10 - Gene-modified cells' effects.
Genenta focuses on innovative therapies targeting solid tumors to enhance immune responses.
Genenta Science (NASDAQ: GNTA) has appointed Tim Obara as Vice President of Business Development. Obara, who previously held senior roles at organizations such as AstraZeneca and GSK, is expected to enhance Genenta's commercial and R&D opportunities, particularly for its Temferon™ treatment. This therapy, currently in a phase 1/2a trial for glioblastoma multiforme patients, employs innovative gene therapy strategies. CEO Pierluigi Paracchi expressed optimism about Obara's experience aiding in the company's growth in solid tumor markets.
Genenta Science (NASDAQ: GNTA) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC on May 2, 2022. The report is available on the company's investor relations website and the SEC's website. Genenta is specializing in hematopoietic stem cell gene therapy, particularly its Temferon™ treatment for Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter. The company emphasizes that forward-looking statements in the report are subject to risks and uncertainties, including those related to ongoing clinical trials.
FAQ
What is the current stock price of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is the market cap of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is Genenta Science's main area of research?
What are some of the key products developed by Genenta Science?
How does Genenta's gene therapy work?
What recent advancements has Genenta Science made?
Where is Genenta Science headquartered?
What is Temferon?
What are TIE2-expressing monocytes (TEMs)?
How does Genenta ensure the safety of their gene therapies?
What is the significance of the Phase 1/2 clinical trials?
Who can I contact for more information about Genenta Science?
